No Detail Found!

Inclisiran Treatment for Cardiovascular Disease Risk Reduction: A Systematic Review and Meta-Analysis

Author(s)
Ya-Fang Chen Department of Cardiology, Tianjin Union Medical Center,Tianjin,China
Si Li Department of Cardiology, Tianjin Union Medical Center,Tianjin,China
Mei-Juan Wang Department of Cardiology, Tianjin Union Medical Center,Tianjin,China
Meng-Yuan Wu Department of Cardiology, Tianjin Union Medical Center,Tianjin,China
Zi-Chen Du Department of Cardiology, Tianjin Union Medical Center,Tianjin,China
Li-Ping Wei Department of Cardiology, Tianjin Union Medical Center,Tianjin,China
Abstract
This study was a meta-analysis of patient data to investigate the therapeutic e ects of inclisiran on LDL-C, PCSK9, and TC in patients with atherosclerosis. Authors searched the Cochrane Library, Pubmed, EMBASE, and Web of Science databases for randomised controlled trials. Data of 4,731 subjects from ve randomised clinical trials were included in this analysis. Patients treated with the PCSK9 inhibitor inclisiran had signi cantly lower LDL-C levels than those treated with placebo or a statin (mean di erence (MD) -1.477; 95% CI -1.551 to -1.403; p <0.001; I2 = 7.2%). The average level of PCSK9 was also relatively lower ((MD) -2.579; 95% CI -2.694 to -2.464; p <0.001; 2I = 36%). They exhibited signi cant reductions in total cholesterol protein levels ((MD) -1.477; 95% CI -1.585 to -1.369; p <0.001; I2 = 46.7%). Inclisiran reduced LDL-C and PCSK9 levels as well as TC and Apo B levels signi cantly in patients with atherosclerotic cardiovascular disease (ASCVD).
Publication Details
Page(s) 1090-1095
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 34, Issue: 9, Year: 2024

Request the full text from PASTIC

Keywords
Atherosclerosis, Meta-analysis, Adverse events, Low-density lipoprotein cholesterol, Inclisiran
0

Citations

0

Downloads

50

Views